Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Market trading guide : Buy Hindustan Zinc, Fortis Health and 2 more stocks for up to 9% gains
2/10/2025
Axis Securities gives Nifty target of 25,500, names Bharti Airtel and Lupin among top 15 picks
2/10/2025
PepsiCo's new challenge : Making its chips and sodas colorful without artificial dyes
2/10/2025
WeWork India IPO : Can investors tag along India's booming Rs 50,000 crore flex space market ?
2/10/2025
Procter & Gamble will shut down business in Pakistan, following Shell and Pfizer exits
2/10/2025
Dubai real estate market 2025 : A thriving global investment hub
2/10/2025
